175 related articles for article (PubMed ID: 33289039)
1. Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting.
Yuen CM; Majidulla A; Jaswal M; Safdar N; Malik AA; Khan AJ; Becerra MC; Keshavjee S; Lu C; Hussain H
Clin Infect Dis; 2021 Sep; 73(5):e1135-e1141. PubMed ID: 33289039
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
Ferguson O; Jo Y; Pennington J; Johnson K; Chaisson RE; Churchyard G; Dowdy D
J Int AIDS Soc; 2020 Oct; 23(10):e25623. PubMed ID: 33073520
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
[TBL] [Abstract][Full Text] [Related]
5. Implementing 3HP vs. IPT as TB preventive treatment in Pakistan.
Jaswal M; Farooq S; Madhani F; Noorani S; Salahuddin N; Amanullah F; Khowaja S; Safdar N; Khan A; Yuen C; Keshavjee S; Becerra M; Hussain H; Malik AA
Int J Tuberc Lung Dis; 2022 Aug; 26(8):741-746. PubMed ID: 35898140
[No Abstract] [Full Text] [Related]
6. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
[TBL] [Abstract][Full Text] [Related]
7. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
[TBL] [Abstract][Full Text] [Related]
8. Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment.
Hussain H; Jaswal M; Farooq S; Safdar N; Madhani F; Noorani S; Shahbaz SS; Salahuddin N; Amanullah F; Khowaja S; Manzar S; Shah JA; Islam Z; Dahri AA; Shahzad M; Keshavjee S; Becerra MC; Khan AJ; Malik AA
Clin Infect Dis; 2023 Aug; 77(4):638-644. PubMed ID: 37083926
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.
Lai WA; Brethour K; D'Silva O; Chaisson RE; Zwerling AA
BMC Public Health; 2022 Dec; 22(1):2292. PubMed ID: 36476206
[TBL] [Abstract][Full Text] [Related]
10. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
[TBL] [Abstract][Full Text] [Related]
11. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Nabunje J; Welishe F; Nakitende A; Akello L; Bishop O; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PPJ; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2021 Dec; 18(12):e1003875. PubMed ID: 34914696
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.
Pease C; Alvarez G; Mallick R; Patterson M; Finn S; Habis Y; Schwartzman K; Kilabuk E; Mulpuru S; Zwerling A
BMJ Open; 2021 May; 11(5):e047514. PubMed ID: 33986067
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Welishe F; Nakitende A; Akello L; Kunihira Tinka L; Nakimuli J; Ritar Kasidi J; Bishop O; Nakasendwa S; Baik Y; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PP; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2024 Feb; 21(2):e1004356. PubMed ID: 38377166
[TBL] [Abstract][Full Text] [Related]
14. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis.
Haas MK; Aiona K; Erlandson KM; Belknap RW
Clin Infect Dis; 2021 Nov; 73(9):e3459-e3467. PubMed ID: 32915203
[TBL] [Abstract][Full Text] [Related]
15. Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics.
Stennis NL; Burzynski JN; Herbert C; Nilsen D; Macaraig M
Clin Infect Dis; 2016 Jan; 62(1):53-59. PubMed ID: 26338781
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
[No Abstract] [Full Text] [Related]
17. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
McClintock AH; Eastment M; McKinney CM; Pitney CL; Narita M; Park DR; Dhanireddy S; Molnar A
BMC Infect Dis; 2017 Feb; 17(1):146. PubMed ID: 28196479
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
Shepardson D; Marks SM; Chesson H; Kerrigan A; Holland DP; Scott N; Tian X; Borisov AS; Shang N; Heilig CM; Sterling TR; Villarino ME; Mac Kenzie WR
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1531-7. PubMed ID: 24200264
[TBL] [Abstract][Full Text] [Related]
19. Isoniazid and Rifapentine Treatment Eradicates Persistent
Foreman TW; Bucşan AN; Mehra S; Peloquin C; Doyle LA; Russell-Lodrigue K; Gandhi NR; Altman J; Day CL; Ernst JD; Blumberg HM; Rengarajan J; Kaushal D
Am J Respir Crit Care Med; 2020 Feb; 201(4):469-477. PubMed ID: 31647877
[No Abstract] [Full Text] [Related]
20. Completion Rates, Adverse Effects, and Costs of a 3-Month and 9-Month Treatment Regimen for Latent Tuberculosis Infection in California Inmates, 2011-2014.
Wheeler C; Mohle-Boetani J
Public Health Rep; 2019; 134(1_suppl):71S-79S. PubMed ID: 31059418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
